NAラジオイムノアッセイ市場 - 産業動向と2030年までの予測NA Radioimmunoassay Market - Industry Trends and Forecast to 2030 北米のラジオイムノアッセイ市場は、2023年から2030年にかけて4.4%の大幅なCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2... もっと見る
サマリー北米のラジオイムノアッセイ市場は、2023年から2030年にかけて4.4%の大幅なCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。市場セグメンテーションを行います: 中東・アフリカのラジオイムノアッセイ市場、製品タイプ別(ラジオイムノアッセイ試薬・キット、ラジオイムノアッセイアナライザー)、用途別(科学研究、臨床診断)、エンドユーザー別(病院、臨床診断ラボ、学術研究機関、製薬・バイオ医薬品業界、受託研究機関、その他)、流通チャネル別(直接入札、オンライン販売、第三者流通、その他)、国別(アメリカ、カナダ、メキシコ) 産業動向および2030年までの予測 北米ラジオイムノアッセイ市場の成長に寄与する主な要因として、以下のものが挙げられます: - 高スループットおよび自動化された手順による、エラーのない正確な結果に対する需要の増加 - 技術的進歩の高まり - 市場関係者の戦略的な取り組み - 医学における研究開発の意義が高まる 市場のプレーヤー: 北米のラジオイムノアッセイ市場の主要な市場関係者は以下の通りです: - パーキンエルマー株式会社 - エムピーバイオメディカルズ - テカントレーディングAG - メルクKGaA - 株式会社イムノバイオロジーラボラトリーズ - EUROIMMUN Medizinische Labordiagnostika AG(ユーロイムン メディジニッシェ ラボルダグノスティカ AG - カミヤバイオメディカル株式会社 - ベックマン・コールター社 - マイバイオソース・ドットコム - Berthold Technologies GmbH & Co.KG - ハイデックスOy. - アブカム・ピーエルシー 目次TABLE OF CONTENTS1 INTRODUCTION 65 1.1 OBJECTIVES OF THE STUDY 65 1.2 MARKET DEFINITION 65 1.3 OVERVIEW OF NORTH AMERICA RADIOIMMUNOASSAY MARKET 65 1.4 LIMITATIONS 67 1.5 MARKETS COVERED 67 2 MARKET SEGMENTATION 71 2.1 MARKETS COVERED 71 2.2 GEOGRAPHICAL SCOPE 72 2.3 YEARS CONSIDERED FOR THE STUDY 73 2.4 CURRENCY AND PRICING 73 2.5 DBMR TRIPOD DATA VALIDATION MODEL 74 2.6 MULTIVARIATE MODELLING 77 2.7 PRODUCT TYPE LIFELINE CURVE 77 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78 2.9 DBMR MARKET POSITION GRID 79 2.10 MARKET TESTING TYPE COVERAGE GRID 81 2.11 VENDOR SHARE ANALYSIS 82 2.12 SECONDARY SOURCES 83 2.13 ASSUMPTIONS 83 3 EXECUTIVE SUMMARY 84 4 PREMIUM INSIGHTS 87 4.1 PESTEL ANALYSIS 88 4.2 PORTYER’S FIVE FORCES 89 4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 90 5 INDUSTRY INSIGHTS: 91 6 REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY 92 6.1 U.S REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY 92 6.2 EUROPE REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 92 6.3 INDIA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 93 6.4 CHINA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 94 7 MARKET OVERVIEW 95 7.1 DRIVERS 97 7.1.1 INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES 97 7.1.2 RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES 97 7.1.3 RISE IN THE TECHNOLOGICAL ADVANCEMENTS 98 7.2 RESTRAINTS 98 7.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS 98 7.2.2 SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS 99 7.2.3 ADVERSE EFFECTS OF HAZARDOUS RADIOACTIVE ELEMENTS 99 7.3 OPPORTUNITIES 100 7.3.1 INCREASING SIGNIFICANCE OF RESEARCH AND DEVELOPMENT IN MEDICAL SCIENCE 100 7.3.2 RISE IN GOVERNMENT FUNDING AND OVERALL HEALTHCARE EXPENDITURE 100 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 101 7.4 CHALLENGES 103 7.4.1 LACK OF SKILLED PROFESSIONALS 103 7.4.2 NEW INNOVATIONS IN VARIOUS OTHER IMMUNOASSAY PROCEDURES 103 8 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 104 8.1 OVERVIEW 105 8.2 RADIOIMMUNOASSAY REAGENTS AND KITS 108 8.2.1 KITS 109 8.2.2 BUFFER 109 8.2.2.1 SOLUTION 109 8.2.2.2 POWDER 109 8.2.3 STANDARD CONCENTRATES 110 8.2.4 PRECIPITATING REAGENTS 110 8.2.5 RADIOISOTOPES 110 8.2.5.1 BETA EMITTERS 110 8.2.5.1.1 TRITIUM 110 8.2.5.1.2 CARBON-14 111 8.2.5.2 GAMMA EMITTERS 111 8.2.5.2.1 IODINE-125 111 8.2.5.2.2 CHROMIUM-51 111 8.2.5.2.3 COBALT-57 111 8.2.6 ANTIBODY/ANTISERUM 112 8.2.6.1 POLYCLONAL 112 8.2.6.2 MONOCLONAL 112 8.2.7 OTHERS 112 8.3 RADIOIMMUNOASSAY ANALYZER 113 9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION 114 9.1 OVERVIEW 115 9.2 SCIENTIFIC RESEARCH 118 9.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS 119 9.2.2 RADIOIMMUNOASSAY ANALYZER 119 9.3 CLINICAL DIAGNOSIS 119 9.3.1 INFECTIOUS DISEASE TESTING 120 9.3.1.1 RADIOIMMUNOASSAY REAGENTS AND KITS 120 9.3.1.2 RADIOIMMUNOASSAY ANALYZER 120 9.3.2 ALLERGY TESTING 121 9.3.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS 121 9.3.2.2 RADIOIMMUNOASSAY ANALYZER 121 9.3.3 ONCOLOGY TESTING 121 9.3.3.1 RADIOIMMUNOASSAY REAGENTS AND KITS 121 9.3.3.2 RADIOIMMUNOASSAY ANALYZER 122 9.3.4 ENDOCRINE TESTING 122 9.3.4.1 RADIOIMMUNOASSAY REAGENTS AND KITS 122 9.3.4.2 RADIOIMMUNOASSAY ANALYZER 122 9.3.5 TOXICOLOGY TESTING 123 9.3.5.1 RADIOIMMUNOASSAY REAGENTS AND KITS 123 9.3.5.2 RADIOIMMUNOASSAY ANALYZER 123 9.3.6 AUTOIMMUNE DISEASE TESTING 123 9.3.6.1 RADIOIMMUNOASSAY REAGENTS AND KITS 124 9.3.6.2 RADIOIMMUNOASSAY ANALYZER 124 9.3.7 OTHER DISEASE TESTING 124 10 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER 125 10.1 OVERVIEW 126 10.2 HOSPITALS 129 10.3 CLINICAL DIAGNOSTIC LABORATORIES 129 10.4 ACADEMIC AND RESEARCH INSTITUTES 130 10.5 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY 131 10.6 CONTRACT RESEARCH ORGANISATIONS 131 10.7 OTHERS 132 11 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL 133 11.1 OVERVIEW 134 11.2 DIRECT TENDER 137 11.3 ONLINE SALES 138 11.4 THIRD PARTY DISTRIBUTIONS 139 11.5 OTHERS 140 12 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY REGION 141 12.1 NORTH AMERICA 142 12.1.1 U.S. 154 12.1.2 CANADA 161 12.1.3 MEXICO 168 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY LANDSCAPE 175 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 175 14 SWOT ANALYSIS 176 15 COMPANY PROFILE 177 15.1 PERKINELMER INC. 177 15.1.1 COMPANY SNAPSHOT 177 15.1.2 REVENUE ANALYSIS 177 15.1.3 COMPANY SHARE ANALYSIS 178 15.1.4 PRODUCT PORTFOLIO 178 15.1.4 RECENT DEVELOPMENT 179 15.2 MERCK KGAA 180 15.2.1 COMPANY SNAPSHOT 180 15.2.2 REVENUE ANALYSIS 180 15.2.3 COMPANY SHARE ANALYSIS 181 15.2.4 PRODUCT PORTFOLIO 181 15.2.5 RECENT DEVELOPMENTS 181 15.3 BECKMAN COULTER, INC. 183 15.3.1 COMPANY SNAPSHOT 183 15.3.2 COMPANY SHARE ANALYSIS 183 15.3.3 PRODUCT PORTFOLIO 183 15.3.4 RECENT DEVELOPMENT 184 15.4 ABCAM PLC 185 15.4.1 COMPANY SNAPSHOT 185 15.4.2 REVENUE ANALYSIS 185 15.4.3 COMPANY SHARE ANALYSIS 186 15.4.4 PRODUCT PORTFOLIO 186 15.4.5 RECENT DEVELOPMENT 186 15.5 TECAN TRADING AG 187 15.5.1 COMPANY SNAPSHOT 187 15.5.2 REVENUE ANALYSIS 187 15.5.3 COMPANY SHARE ANALYSIS 188 15.5.4 PRODUCT PORTFOLIO 188 15.5.5 RECENT DEVELOPMENT 189 15.6 BERTHOLD TECHNOLOGIES GMBH & CO.KG 190 15.6.1 COMPANY SNAPSHOT 190 15.6.2 PRODUCT PORTFOLIO 190 15.6.3 RECENT DEVELOPMENTS 190 15.7 DEMEDITEC DIAGNOSTICS GMBH 191 15.7.1 COMPANY SNAPSHOT 191 15.7.2 PRODUCT PORTFOLIO 191 15.7.3 RECENT DEVELOPMENTS 192 15.8 DIASOURCE 193 15.8.1 COMPANY SNAPSHOT 193 15.8.2 PRODUCT PORTFOLIO 193 15.8.3 RECENT DEVELOPMENT 193 15.9 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 194 15.9.1 COMPANY SNAPSHOT 194 15.9.2 PRODUCT PORTFOLIO 194 15.9.3 RECENT DEVELOPMENTS 194 15.10 HIDEX OY 196 15.10.1 COMPANY SNAPSHOT 196 15.10.2 PRODUCT PORTFOLIO 196 15.10.3 RECENT DEVELOPMENTS 196 15.11 IMMUNO-BIOLOGICAL LABORATORIES CO,LTD. 197 15.11.1 COMPANY SNAPSHOT 197 15.11.2 PRODUCT PORTFOLIO 197 15.11.3 RECENT DEVELOPMENT 199 15.12 INSTITUTE OF ISOTOPES 200 15.12.1 COMPANY SNAPSHOT 200 15.12.2 PRODUCT PORTFOLIO 200 15.12.3 RECENT DEVELOPMENTS 201 15.13 KAMIYA BIOMEDICAL COMPANY 202 15.13.1 COMPANY SNAPSHOT 202 15.13.2 PRODUCT PORTFOLIO 202 15.13.3 RECENT DEVELOPMENTS 202 15.14 MP BIOMEDICALS 203 15.14.1 COMPANY SNAPSHOT 203 15.14.2 PRODUCT PORTFOLIO 203 15.14.3 RECENT DEVELOPMENTS 204 15.15 MYBIOSOURCE.COM. 205 15.15.1 COMPANY SNAPSHOT 205 15.15.2 PRODUCT PORTFOLIO 205 15.15.3 RECENT DEVELOPMENT 205 16 QUESTIONNAIRE 206 17 RELATED REPORTS 209 図表リストLIST OF TABLESTABLE 1 LIST OF IN-VITRO DIAGNOSTIC MEDICAL DEVICES (IVD ANALYZERS) UNDER PROVISIONS OF SUB-RULE (2) RULE 4 OF THE MEDICAL DEVICES RULES, 2017 48 TABLE 2 COST OF RIA KITS IS MENTIONED BELOW 53 TABLE 3 DECOMPOSITION RATES OF A FEW RADIOLABELED ISOTOPES ARE MENTIONED IN THE BELOW TABLE 54 TABLE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 62 TABLE 5 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 63 TABLE 6 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64 TABLE 7 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64 TABLE 8 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65 TABLE 9 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65 TABLE 10 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66 TABLE 11 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67 TABLE 12 NORTH AMERICA RADIOIMMUNOASSAY ANALYZER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 68 TABLE 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 72 TABLE 14 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 73 TABLE 15 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73 TABLE 16 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74 TABLE 17 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 75 TABLE 18 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 75 TABLE 19 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76 TABLE 20 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76 TABLE 21 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77 TABLE 22 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 78 TABLE 23 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 78 TABLE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 83 TABLE 25 NORTH AMERICA HOSPITALS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 84 TABLE 26 NORTH AMERICA CLINICAL DIAGNOSTIC LABORATORIES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85 TABLE 27 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85 TABLE 28 NORTH AMERICA PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 86 TABLE 29 NORTH AMERICA CONTRACT RESEARCH ORGANISATIONS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87 TABLE 30 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87 TABLE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 91 TABLE 32 NORTH AMERICA DIRECT TENDER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 92 TABLE 33 NORTH AMERICA ONLINE SALES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 93 TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTION IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 94 TABLE 35 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 95 TABLE 36 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 101 TABLE 37 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 101 TABLE 38 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 101 TABLE 39 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 102 TABLE 40 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 102 TABLE 41 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 102 TABLE 42 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 102 TABLE 43 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 102 TABLE 44 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103 TABLE 45 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103 TABLE 46 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 103 TABLE 47 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 103 TABLE 48 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103 TABLE 49 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 104 TABLE 50 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 104 TABLE 51 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 104 TABLE 52 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 104 TABLE 53 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 104 TABLE 54 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 105 TABLE 55 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 105 TABLE 56 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 105 TABLE 57 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 105 TABLE 58 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 106 TABLE 59 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106 TABLE 60 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106 TABLE 61 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107 TABLE 62 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107 TABLE 63 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 107 TABLE 64 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107 TABLE 65 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 108 TABLE 66 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108 TABLE 67 U.S. RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109 TABLE 68 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109 TABLE 69 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 109 TABLE 70 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 110 TABLE 71 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110 TABLE 72 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 110 TABLE 73 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 110 TABLE 74 U.S. RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110 TABLE 75 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111 TABLE 76 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 111 TABLE 77 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 111 TABLE 78 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111 TABLE 79 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 111 TABLE 80 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 112 TABLE 81 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 112 TABLE 82 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 112 TABLE 83 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 112 TABLE 84 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 112 TABLE 85 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 113 TABLE 86 U.S. RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113 TABLE 87 U.S. SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113 TABLE 88 U.S. CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113 TABLE 89 U.S. INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 90 U.S. ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 91 U.S. ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 92 U.S. ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 93 U.S. TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 115 TABLE 94 U.S. AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 115 TABLE 95 U.S. RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115 TABLE 96 U.S. RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115 TABLE 97 CANADA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116 TABLE 98 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116 TABLE 99 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 116 TABLE 100 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 117 TABLE 101 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117 TABLE 102 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 117 TABLE 103 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 117 TABLE 104 CANADA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117 TABLE 105 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118 TABLE 106 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 118 TABLE 107 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 118 TABLE 108 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118 TABLE 109 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 118 TABLE 110 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 119 TABLE 111 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 119 TABLE 112 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 119 TABLE 113 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 119 TABLE 114 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 119 TABLE 115 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 120 TABLE 116 CANADA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120 TABLE 117 CANADA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120 TABLE 118 CANADA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120 TABLE 119 CANADA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 120 CANADA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 121 CANADA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 122 CANADA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 123 CANADA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 122 TABLE 124 CANADA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122 TABLE 125 CANADA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 122 TABLE 126 CANADA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 122 TABLE 127 MEXICO RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123 TABLE 128 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123 TABLE 129 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 123 TABLE 130 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 124 TABLE 131 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124 TABLE 132 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 124 TABLE 133 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 124 TABLE 134 MEXICO RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124 TABLE 135 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 125 TABLE 136 MEXICO
SummaryNorth America radioimmunoassay market is projected to register a substantial CAGR of 4.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 65 1.1 OBJECTIVES OF THE STUDY 65 1.2 MARKET DEFINITION 65 1.3 OVERVIEW OF NORTH AMERICA RADIOIMMUNOASSAY MARKET 65 1.4 LIMITATIONS 67 1.5 MARKETS COVERED 67 2 MARKET SEGMENTATION 71 2.1 MARKETS COVERED 71 2.2 GEOGRAPHICAL SCOPE 72 2.3 YEARS CONSIDERED FOR THE STUDY 73 2.4 CURRENCY AND PRICING 73 2.5 DBMR TRIPOD DATA VALIDATION MODEL 74 2.6 MULTIVARIATE MODELLING 77 2.7 PRODUCT TYPE LIFELINE CURVE 77 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78 2.9 DBMR MARKET POSITION GRID 79 2.10 MARKET TESTING TYPE COVERAGE GRID 81 2.11 VENDOR SHARE ANALYSIS 82 2.12 SECONDARY SOURCES 83 2.13 ASSUMPTIONS 83 3 EXECUTIVE SUMMARY 84 4 PREMIUM INSIGHTS 87 4.1 PESTEL ANALYSIS 88 4.2 PORTYER’S FIVE FORCES 89 4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 90 5 INDUSTRY INSIGHTS: 91 6 REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY 92 6.1 U.S REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY 92 6.2 EUROPE REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 92 6.3 INDIA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 93 6.4 CHINA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 94 7 MARKET OVERVIEW 95 7.1 DRIVERS 97 7.1.1 INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES 97 7.1.2 RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES 97 7.1.3 RISE IN THE TECHNOLOGICAL ADVANCEMENTS 98 7.2 RESTRAINTS 98 7.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS 98 7.2.2 SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS 99 7.2.3 ADVERSE EFFECTS OF HAZARDOUS RADIOACTIVE ELEMENTS 99 7.3 OPPORTUNITIES 100 7.3.1 INCREASING SIGNIFICANCE OF RESEARCH AND DEVELOPMENT IN MEDICAL SCIENCE 100 7.3.2 RISE IN GOVERNMENT FUNDING AND OVERALL HEALTHCARE EXPENDITURE 100 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 101 7.4 CHALLENGES 103 7.4.1 LACK OF SKILLED PROFESSIONALS 103 7.4.2 NEW INNOVATIONS IN VARIOUS OTHER IMMUNOASSAY PROCEDURES 103 8 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 104 8.1 OVERVIEW 105 8.2 RADIOIMMUNOASSAY REAGENTS AND KITS 108 8.2.1 KITS 109 8.2.2 BUFFER 109 8.2.2.1 SOLUTION 109 8.2.2.2 POWDER 109 8.2.3 STANDARD CONCENTRATES 110 8.2.4 PRECIPITATING REAGENTS 110 8.2.5 RADIOISOTOPES 110 8.2.5.1 BETA EMITTERS 110 8.2.5.1.1 TRITIUM 110 8.2.5.1.2 CARBON-14 111 8.2.5.2 GAMMA EMITTERS 111 8.2.5.2.1 IODINE-125 111 8.2.5.2.2 CHROMIUM-51 111 8.2.5.2.3 COBALT-57 111 8.2.6 ANTIBODY/ANTISERUM 112 8.2.6.1 POLYCLONAL 112 8.2.6.2 MONOCLONAL 112 8.2.7 OTHERS 112 8.3 RADIOIMMUNOASSAY ANALYZER 113 9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION 114 9.1 OVERVIEW 115 9.2 SCIENTIFIC RESEARCH 118 9.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS 119 9.2.2 RADIOIMMUNOASSAY ANALYZER 119 9.3 CLINICAL DIAGNOSIS 119 9.3.1 INFECTIOUS DISEASE TESTING 120 9.3.1.1 RADIOIMMUNOASSAY REAGENTS AND KITS 120 9.3.1.2 RADIOIMMUNOASSAY ANALYZER 120 9.3.2 ALLERGY TESTING 121 9.3.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS 121 9.3.2.2 RADIOIMMUNOASSAY ANALYZER 121 9.3.3 ONCOLOGY TESTING 121 9.3.3.1 RADIOIMMUNOASSAY REAGENTS AND KITS 121 9.3.3.2 RADIOIMMUNOASSAY ANALYZER 122 9.3.4 ENDOCRINE TESTING 122 9.3.4.1 RADIOIMMUNOASSAY REAGENTS AND KITS 122 9.3.4.2 RADIOIMMUNOASSAY ANALYZER 122 9.3.5 TOXICOLOGY TESTING 123 9.3.5.1 RADIOIMMUNOASSAY REAGENTS AND KITS 123 9.3.5.2 RADIOIMMUNOASSAY ANALYZER 123 9.3.6 AUTOIMMUNE DISEASE TESTING 123 9.3.6.1 RADIOIMMUNOASSAY REAGENTS AND KITS 124 9.3.6.2 RADIOIMMUNOASSAY ANALYZER 124 9.3.7 OTHER DISEASE TESTING 124 10 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER 125 10.1 OVERVIEW 126 10.2 HOSPITALS 129 10.3 CLINICAL DIAGNOSTIC LABORATORIES 129 10.4 ACADEMIC AND RESEARCH INSTITUTES 130 10.5 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY 131 10.6 CONTRACT RESEARCH ORGANISATIONS 131 10.7 OTHERS 132 11 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL 133 11.1 OVERVIEW 134 11.2 DIRECT TENDER 137 11.3 ONLINE SALES 138 11.4 THIRD PARTY DISTRIBUTIONS 139 11.5 OTHERS 140 12 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY REGION 141 12.1 NORTH AMERICA 142 12.1.1 U.S. 154 12.1.2 CANADA 161 12.1.3 MEXICO 168 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY LANDSCAPE 175 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 175 14 SWOT ANALYSIS 176 15 COMPANY PROFILE 177 15.1 PERKINELMER INC. 177 15.1.1 COMPANY SNAPSHOT 177 15.1.2 REVENUE ANALYSIS 177 15.1.3 COMPANY SHARE ANALYSIS 178 15.1.4 PRODUCT PORTFOLIO 178 15.1.4 RECENT DEVELOPMENT 179 15.2 MERCK KGAA 180 15.2.1 COMPANY SNAPSHOT 180 15.2.2 REVENUE ANALYSIS 180 15.2.3 COMPANY SHARE ANALYSIS 181 15.2.4 PRODUCT PORTFOLIO 181 15.2.5 RECENT DEVELOPMENTS 181 15.3 BECKMAN COULTER, INC. 183 15.3.1 COMPANY SNAPSHOT 183 15.3.2 COMPANY SHARE ANALYSIS 183 15.3.3 PRODUCT PORTFOLIO 183 15.3.4 RECENT DEVELOPMENT 184 15.4 ABCAM PLC 185 15.4.1 COMPANY SNAPSHOT 185 15.4.2 REVENUE ANALYSIS 185 15.4.3 COMPANY SHARE ANALYSIS 186 15.4.4 PRODUCT PORTFOLIO 186 15.4.5 RECENT DEVELOPMENT 186 15.5 TECAN TRADING AG 187 15.5.1 COMPANY SNAPSHOT 187 15.5.2 REVENUE ANALYSIS 187 15.5.3 COMPANY SHARE ANALYSIS 188 15.5.4 PRODUCT PORTFOLIO 188 15.5.5 RECENT DEVELOPMENT 189 15.6 BERTHOLD TECHNOLOGIES GMBH & CO.KG 190 15.6.1 COMPANY SNAPSHOT 190 15.6.2 PRODUCT PORTFOLIO 190 15.6.3 RECENT DEVELOPMENTS 190 15.7 DEMEDITEC DIAGNOSTICS GMBH 191 15.7.1 COMPANY SNAPSHOT 191 15.7.2 PRODUCT PORTFOLIO 191 15.7.3 RECENT DEVELOPMENTS 192 15.8 DIASOURCE 193 15.8.1 COMPANY SNAPSHOT 193 15.8.2 PRODUCT PORTFOLIO 193 15.8.3 RECENT DEVELOPMENT 193 15.9 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 194 15.9.1 COMPANY SNAPSHOT 194 15.9.2 PRODUCT PORTFOLIO 194 15.9.3 RECENT DEVELOPMENTS 194 15.10 HIDEX OY 196 15.10.1 COMPANY SNAPSHOT 196 15.10.2 PRODUCT PORTFOLIO 196 15.10.3 RECENT DEVELOPMENTS 196 15.11 IMMUNO-BIOLOGICAL LABORATORIES CO,LTD. 197 15.11.1 COMPANY SNAPSHOT 197 15.11.2 PRODUCT PORTFOLIO 197 15.11.3 RECENT DEVELOPMENT 199 15.12 INSTITUTE OF ISOTOPES 200 15.12.1 COMPANY SNAPSHOT 200 15.12.2 PRODUCT PORTFOLIO 200 15.12.3 RECENT DEVELOPMENTS 201 15.13 KAMIYA BIOMEDICAL COMPANY 202 15.13.1 COMPANY SNAPSHOT 202 15.13.2 PRODUCT PORTFOLIO 202 15.13.3 RECENT DEVELOPMENTS 202 15.14 MP BIOMEDICALS 203 15.14.1 COMPANY SNAPSHOT 203 15.14.2 PRODUCT PORTFOLIO 203 15.14.3 RECENT DEVELOPMENTS 204 15.15 MYBIOSOURCE.COM. 205 15.15.1 COMPANY SNAPSHOT 205 15.15.2 PRODUCT PORTFOLIO 205 15.15.3 RECENT DEVELOPMENT 205 16 QUESTIONNAIRE 206 17 RELATED REPORTS 209 List of Tables/GraphsLIST OF TABLESTABLE 1 LIST OF IN-VITRO DIAGNOSTIC MEDICAL DEVICES (IVD ANALYZERS) UNDER PROVISIONS OF SUB-RULE (2) RULE 4 OF THE MEDICAL DEVICES RULES, 2017 48 TABLE 2 COST OF RIA KITS IS MENTIONED BELOW 53 TABLE 3 DECOMPOSITION RATES OF A FEW RADIOLABELED ISOTOPES ARE MENTIONED IN THE BELOW TABLE 54 TABLE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 62 TABLE 5 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 63 TABLE 6 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64 TABLE 7 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64 TABLE 8 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65 TABLE 9 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65 TABLE 10 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66 TABLE 11 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67 TABLE 12 NORTH AMERICA RADIOIMMUNOASSAY ANALYZER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 68 TABLE 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 72 TABLE 14 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 73 TABLE 15 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73 TABLE 16 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74 TABLE 17 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 75 TABLE 18 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 75 TABLE 19 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76 TABLE 20 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76 TABLE 21 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77 TABLE 22 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 78 TABLE 23 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 78 TABLE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 83 TABLE 25 NORTH AMERICA HOSPITALS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 84 TABLE 26 NORTH AMERICA CLINICAL DIAGNOSTIC LABORATORIES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85 TABLE 27 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85 TABLE 28 NORTH AMERICA PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 86 TABLE 29 NORTH AMERICA CONTRACT RESEARCH ORGANISATIONS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87 TABLE 30 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87 TABLE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 91 TABLE 32 NORTH AMERICA DIRECT TENDER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 92 TABLE 33 NORTH AMERICA ONLINE SALES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 93 TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTION IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 94 TABLE 35 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 95 TABLE 36 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 101 TABLE 37 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 101 TABLE 38 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 101 TABLE 39 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 102 TABLE 40 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 102 TABLE 41 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 102 TABLE 42 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 102 TABLE 43 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 102 TABLE 44 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103 TABLE 45 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103 TABLE 46 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 103 TABLE 47 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 103 TABLE 48 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103 TABLE 49 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 104 TABLE 50 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 104 TABLE 51 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 104 TABLE 52 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 104 TABLE 53 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 104 TABLE 54 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 105 TABLE 55 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 105 TABLE 56 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 105 TABLE 57 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 105 TABLE 58 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 106 TABLE 59 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106 TABLE 60 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106 TABLE 61 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107 TABLE 62 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107 TABLE 63 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 107 TABLE 64 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107 TABLE 65 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 108 TABLE 66 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108 TABLE 67 U.S. RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109 TABLE 68 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109 TABLE 69 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 109 TABLE 70 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 110 TABLE 71 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110 TABLE 72 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 110 TABLE 73 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 110 TABLE 74 U.S. RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110 TABLE 75 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111 TABLE 76 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 111 TABLE 77 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 111 TABLE 78 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111 TABLE 79 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 111 TABLE 80 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 112 TABLE 81 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 112 TABLE 82 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 112 TABLE 83 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 112 TABLE 84 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 112 TABLE 85 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 113 TABLE 86 U.S. RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113 TABLE 87 U.S. SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113 TABLE 88 U.S. CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113 TABLE 89 U.S. INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 90 U.S. ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 91 U.S. ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 92 U.S. ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114 TABLE 93 U.S. TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 115 TABLE 94 U.S. AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 115 TABLE 95 U.S. RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115 TABLE 96 U.S. RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115 TABLE 97 CANADA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116 TABLE 98 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116 TABLE 99 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 116 TABLE 100 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 117 TABLE 101 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117 TABLE 102 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 117 TABLE 103 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 117 TABLE 104 CANADA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117 TABLE 105 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118 TABLE 106 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 118 TABLE 107 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 118 TABLE 108 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118 TABLE 109 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 118 TABLE 110 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 119 TABLE 111 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 119 TABLE 112 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 119 TABLE 113 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 119 TABLE 114 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 119 TABLE 115 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 120 TABLE 116 CANADA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120 TABLE 117 CANADA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120 TABLE 118 CANADA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120 TABLE 119 CANADA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 120 CANADA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 121 CANADA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 122 CANADA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121 TABLE 123 CANADA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 122 TABLE 124 CANADA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122 TABLE 125 CANADA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 122 TABLE 126 CANADA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 122 TABLE 127 MEXICO RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123 TABLE 128 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123 TABLE 129 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 123 TABLE 130 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 124 TABLE 131 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124 TABLE 132 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 124 TABLE 133 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 124 TABLE 134 MEXICO RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124 TABLE 135 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 125 TABLE 136 MEXICO
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
Data Bridge Market Research社の医療デバイス分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |